XML 30 R17.htm IDEA: XBRL DOCUMENT v3.19.3
Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2019
Accounting Policies [Abstract]  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of financial instruments that are measured at fair value as of September 30, 2019.

 

    Carrying     Fair Value Measurement Using  
    Value     Level 1     Level 2     Level 3     Total  
                               
Marketable securities                              
Derivative warrants liabilities   $ (334,972 )   $     $     $ (334,972 )   $ (334,972 )

 

The following table provides a summary of financial instruments that are measured at fair value as of December 31, 2018.

 

    Carrying     Fair Value Measurement Using  
    Value     Level 1     Level 2     Level 3     Total  
                               
Marketable securities     250,388       250,388                   250,388  
Derivative warrants liabilities   $ (676,079 )   $     $     $ (676,079 )   $ (676,079 )

Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation

The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the nine months ended September 30, 2019 and the year ended December 31, 2018:

 

   

Fair Value Measurement

Using Level 3

 
    Inputs Total  
Balance, December 31, 2017   $ 425,838  
Change in fair value of derivative warrants liabilities     250,241  
Balance, December 31, 2018     676,079  
Change in fair value of derivative warrants liabilities     (341,107 )
Balance, September 30, 2019   $ 334,972  

Schedule of Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques

The following assumptions:

 

   

December 31,

2018

   

September 30,

2019

 
Exercise price     1.25       1.25  
Risk free interest rate     2.46 %     1.63 %
Dividend yield     0.00 %     0.00 %
Expected volatility     152 %     123 %
Contractual term     2.15 Years       1.40 Years  

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The effect of dilution on net loss becomes anti-dilutive and therefore is not reflected on the income statement.

 

    Potentially Outstanding
Dilutive Common Shares
 
    For the Nine Months Ended
September 30, 2019
    For the Nine Months Ended
September 30, 2018
 
             
Conversion Feature Shares                
                 
Common shares issuable under the conversion feature of preferred shares     872,766       872,766  
                 
Stock Options     3,972,866       3,846,299  
                 
Warrants     3,826,658       3,826,658  
                 
Total potentially outstanding dilutive common shares     8,672,290       8,545,723